Individual Participants

EXPLORA BIOTECH SRL (EXP – ITALY) is a privately owned Italian company established in 2006 at the Technological Park “Tecnopolo Tiburtino” in Rome by a pool of young researchers and the support from a French seed capital organization INVENT SaS. EXP is committed to the development of innovative technologies and products for the Life Science community and develop innovative applications in the field of biological engineering. Explora’s hallmark is the multidisciplinary approach, indeed Explora’s team gather together material scientists, biotechnologists and medical practitioners to deliver innovative and effective solution to unmet medical needs. EXP is currently involved in 4 European and international research projects. Within the framework of the THE GRAIL project EXP will oversees project coordination (WP1), dissemination (WP8) and lead the in vivo experiment tests (WP 6) in addition to leveraging its experience in material bio-conjugation and functionalization (WP2) capitalizing on previous work carried out during other EU projects, such as the EU FP7 MAGISTER projects.


DONAWA LIFESCIENCE CONSULTING SRL (DLC – ITALY) provides medical device EU and US Quality and Regulatory consultancy services, assisting clients from initial feasibility work to successful product launch and beyond. In the context of this project, DLC will provide regulatory and quality system advice (WP7) and practical support throughout the project, including: regulatory strategy, training on design controls, implementation of design controls, drafting of required technical documentation, including biocompatibility studies and identification and liaison with a suitable Notified Body.


TECHNICAL PROTEINS NANOBIOTECHNOLOGY SL (TPNBT – SPAIN) is a biotech SME with expertise in recombinant biomaterials and devices focussed on developing innovative solutions to medical problems. TPNBT designs and produces biomaterials and devices based on recombinant protein polymers that are distributed to an international market. TPNBT is a spin-off company created in 2010 by three researchers of the University of Valladolid who have a broad expertise in the production of recombinant elastin-like polymers. TPNBT will take care of the leadership of WP2 dealing with material design, synthesis and processing.


CONIC VASCULAR TECHNOLOGY S.A. (SWITZERLAND) is a Swiss Company, dedicated to developing and manufacturing medical devices for Cardiovascular Technology and Interventional Radiology, Balloon Catheters (both peripheral and coronary) and Stent. The Conic Vascular headquarters are located in Lugano (Switzerland), as well as Administration, Distribution, Sales and Marketing, and Logistics. Continuing this project, Conic Vascular was also established in Bertamiráns (Spain) a Manufacture Plant, forming a large group interested in finding new ideas to innovate and develop innovative, competent and quality to improve and ensure the welfare of consumers and patients. In the THE GRAIL project CV will lead the work package committed to the design and Upscaling of medical device (WP5).


UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II. (CRIB – ITALY) The Interdisciplinary Research Centre in Biomaterials (CRIB) at the University of Naples Federico II is recognized as a leading European Academic Institution in the field of biomaterials, tissue engineering and drug delivery. CRIB co-ordinates research in various areas of biomedical applications (materials science, advanced therapy and diagnostics, orthopedics, cardiovascular, tissue reconstruction and tissue engineering). The role of CRIB in the GRAIL project is focused on the development of a functional material with specific chemical-physical and microstructural properties to be used in the in vivo tissue engineering of intima.


UNIVERSITAIR MEDISCH CENTRUM UTRECHT (UMCU – NETHERLANDS) is a leading international university medical center. Its core activities are to carry out cutting-edge scientific research from bench to bedside; to provide state-of-the-art healthcare that requires special knowledge and expertise; and to offer excellent healthcare programs and training to students, medical and biomedical researchers, doctors and other academic professionals. In the THE GRAIL project UMCU will oversees the in vivo experiments on large animals (WP6).


FUNDACIÓ PRIVADA INSTITUT DE BIOENGINYERIA DE CATALUNYA (IBEC – SPAIN). The Institute for Bioengineering of Catalunya, located in Barcelona, aims to develop interdisciplinary research of excellence ranging from basic to technological research in the field of bioengineering and nanomedicine. The bio/non-bio interactions for regenerative medicine research group, led by Prof. Dr. Josep A. Planell, focuses on the development of substrate materials that deliver to stem cells the appropriate and specific biological signals able to trigger and guide cell activity for tissue regeneration (WP3).


THE UNIVERSITY OF LIVERPOOL (UniLiv – UNITED KINGDOM). The UK Centre for Tissue Engineering (UKCTE) was established at the University of Liverpool, Department of Clinical Engineering following the building of the €5M state-of-the-art Biomaterials and Tissue Engineering Laboratory. The group has an extensive track record and global recognition in biomaterials, biocompatibility and tissue engineering research, involving animal models for the study and quantification of biocompatibility parameters, design and fabrication of TE scaffolds and the study of blood, soft tissue, mesenchymal and haematopoietic adult stem cells. The University of Liverpool is responsible for leading the cell, blood and rodent-based cytoxicity and biocompatibility tasks (WP 3).


UNIVERSIDAD DE VALLADOLID (UVa – SPAIN) is a pioneer and world leading group in the use of genetic engineering and other molecular biology tools to obtain protein-like polymers and materials. With these techniques, the team has already designed, bioproduced and characterized a wide set of highly functional genetically engineered protein polymers with absolute controlled molecular architecture and sequences. All those polymers are characterized by being tailored and multi(bio)functional including in their sequence various cell attachment sequences and other bioactive peptide domains. UVa will liverage its competence in WP2 dealing with material design, synthesis and processing.